Trade Names:Ceptaz- Powder for Injection 1 g (as pentahydrate w/L-arginine)- Powder for Injection 2 g (as pentahydrate w/L-arginine)
Trade Names:Fortaz- Powder for Injection 500 mg (2.3 mEq sodium/g)- Powder for Injection 1 g (2.3 mEq sodium/g)- Powder for Injection 2 g (2.3 mEq sodium/g)- Powder for Injection 6 g (2.3 mEq sodium/g)- Injection 1 g with 2.2 g dextrose hydrous- Injection 2 g with 1.6 g dextrose hydrous
Trade Names:Tazicef- Powder for Injection 1 g (2.3 mEq sodium/g)- Powder for Injection 2 g (2.3 mEq sodium/g)- Powder for Injection 6 g (2.3 mEq sodium/g)- Injection 1 g- Injection 2 g
Trade Names:Tazidime- Powder for Injection 500 mg (as pentahydrate w/L-arginine)- Powder for Injection 1 g (as pentahydrate w/L-arginine)- Powder for Injection 2 g (as pentahydrate w/L-arginine)- Powder for Injection 6 g (as pentahydrate w/L-arginine)
Inhibits mucopeptide synthesis in bacterial cell wall.
C max is 45 to 90 mcg/mL (500 mg and 1 g doses).IM
C max is 17 to 39 mcg/mL (500 mg and 1 g doses). T max is about 1 h.
Ceftazidime is less than 10% protein bound. It is excreted in human milk in low concentrations.
The t ½ is about 1.9 to 2 h. About 80% to 90% is excreted unchanged by the kidneys. Renal Cl is about 100 mL/min. Plasma Cl is about 115 mL/min.
The t ½ is significantly prolonged. Dosage adjustments are recommended.
Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms; concomitant antibiotic therapy.
Hypersensitivity to cephalosporins.
IV/IM 250 mg to 2 g every 8 to 12 h.Children 1 mo to 12 yr of age
IV 30 to 50 mg/kg every 8 h (max, 6 g/day).Newborns younger than 4 wk of age
IV 30 mg/kg every 12 h.
Store sterile powder at room temperature and protect from light. When reconstituted with sterile water for injection, solution is stable for 7 days if refrigerated and for 18 to 24 h when stored at room temperature. If frozen immediately after reconstitution, solution is stable for 3 mo. Completely thaw frozen preparation at room temperature before use. After thawing, solution may be stored for 18 to 24 h at room temperature or 4 days in refrigerator. Do not refreeze.
Increased risk of nephrotoxicity.
Do not add aminoglycosides to ceftazidime solutions because inactivation of both drugs may result; administer at separate sites if concurrent therapy is indicated.Sodium bicarbonate
Do not dilute ceftazidime with sodium bicarbonate.
May cause false-positive urine glucose test results with Benedict solution, Fehling solution, or Clinitest tablets but not with enzyme-based tests (eg, Clinistix , Tes-Tape ); false-positive test results for proteinuria with acid and denaturization-precipitation tests; false-positive direct Coombs test result in certain patients (eg, those with azotemia); false elevations in urinary 17-ketosteroid values.
Nausea; vomiting; diarrhea; anorexia; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis.
Pyuria; renal dysfunction; dysuria; reversible interstitial nephritis; hematuria; toxic nephropathy.
Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; thrombocytosis; decreased platelet function; anemia; aplastic anemia; hemorrhage.
Hepatic function impairment; cholestatic jaundice; abnormal LFT results.
Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis; candidal overgrowth; serum sickness–like reactions (eg, skin rashes, polyarthritis, arthralgia, fever); phlebitis; thrombophlebitis, and pain at injection site.
MonitorResponse to therapy
Monitor patient's response to therapy. Notify health care provider if infection does not appear to improve or worsens.Adverse reactions
Monitor patient for GI, DERM, and general body adverse reactions, and signs of superinfection. Inform health care provider if noted and significant. Immediately report severe diarrhea, diarrhea containing blood or pus, or severe abdominal cramping.
Category B .
Excreted in breast milk.
Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients because of possible cross-reactivity.
Use drug with caution in patients with renal function impairment. Dosage adjustment based on renal function may be required.
May result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Consider in patients in whom diarrhea develops.
Neuromuscular excitability, asterixis, seizures, encephalopathy.
Copyright © 2009 Wolters Kluwer Health.